25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NBY (Novabay) Stock Analysis
Buy, Hold or Sell?

Let's analyze Novabay together

I guess you are interested in NovaBay Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Novabay’s Financial Insights
  • 📈 Technical Analysis (TA) – Novabay’s Price Targets

I'm going to help you getting a better view of NovaBay Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about NovaBay Pharmaceuticals Inc

I send you an email if I find something interesting about NovaBay Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Novabay (30 sec.)










1.2. What can you expect buying and holding a share of Novabay? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.06
Expected worth in 1 year
$2.09
How sure are you?
37.5%

+ What do you gain per year?

Total Gains per Share
$1.03
Return On Investment
187.8%

For what price can you sell your share?

Current Price per Share
$0.55
Expected price per share
$0.44 - $0.635
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Novabay (5 min.)




Live pricePrice per Share (EOD)
$0.55
Intrinsic Value Per Share
$-4.01 - $1.71
Total Value Per Share
$-2.95 - $2.77

2.2. Growth of Novabay (5 min.)




Is Novabay growing?

Current yearPrevious yearGrowGrow %
How rich?$6.1m$4.7m-$3.1m-193.8%

How much money is Novabay making?

Current yearPrevious yearGrowGrow %
Making money$915.2k-$3.2m$4.1m458.1%
Net Profit Margin41.0%-93.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Novabay (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#642 / 886

Most Revenue
#404 / 886

Most Profit
#143 / 886
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Novabay?

Welcome investor! Novabay's management wants to use your money to grow the business. In return you get a share of Novabay.

First you should know what it really means to hold a share of Novabay. And how you can make/lose money.

Speculation

The Price per Share of Novabay is $0.55. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Novabay.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Novabay, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.06. Based on the TTM, the Book Value Change Per Share is $0.26 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.38 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Novabay.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps1.32239.8%0.1628.6%-0.56-102.5%-0.39-71.2%-0.37-67.9%-0.42-75.8%
Usd Book Value Change Per Share1.08196.8%0.2646.9%-0.38-68.2%-0.17-30.2%0.0610.2%0.023.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.08196.8%0.2646.9%-0.38-68.2%-0.17-30.2%0.0610.2%0.023.1%
Usd Price Per Share0.59-1.02-0.38-0.80-0.75-1.49-
Price to Earnings Ratio0.11--0.87--0.19--0.52--0.69--0.85-
Price-to-Total Gains Ratio0.54--4.13--3.90--3.55--1.28--0.23-
Price to Book Ratio0.55--10.91-1.26--3.02--1.36-1.02-
Price-to-Total Gains Ratio0.54--4.13--3.90--3.55--1.28--0.23-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.55
Number of shares1818
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.260.06
Usd Total Gains Per Share0.260.06
Gains per Quarter (1818 shares)469.41101.84
Gains per Year (1818 shares)1,877.64407.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10187818680407397
20375537460815804
3056335624012221211
4075117502016291618
5093889380020372025
601126611258024442432
701314313136028512839
801502115014032593246
901689916892036663653
1001877618770040734060

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%2.038.00.05.0%7.068.00.09.3%
Book Value Change Per Share2.02.00.050.0%2.010.00.016.7%7.013.00.035.0%15.025.00.037.5%28.047.00.037.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.075.00.0%
Total Gains per Share2.02.00.050.0%2.010.00.016.7%7.013.00.035.0%15.025.00.037.5%28.047.00.037.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of NovaBay Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.0820.258+319%-0.375+135%-0.166+115%0.056+1832%0.017+6168%
Book Value Per Share--1.0600.279+280%0.820+29%1.068-1%1.386-23%0.903+17%
Current Ratio--2.9471.350+118%1.558+89%1.832+61%2.758+7%2.520+17%
Debt To Asset Ratio--0.3750.823-54%0.630-40%0.602-38%0.501-25%0.689-46%
Debt To Equity Ratio--0.6010.804-25%8.976-93%3.444-83%2.843-79%3.780-84%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--8164477.0004787439.655+71%-637721.260+108%2554819.632+220%4599377.557+78%7497086.044+9%
Eps--1.3190.157+738%-0.564+143%-0.392+130%-0.374+128%-0.417+132%
Ev To Ebitda Ratio---0.613-1.098+79%0.096-738%-0.030-95%-0.485-21%-0.532-13%
Ev To Sales Ratio--0.8840.506+75%-0.066+107%0.235+276%0.527+68%0.668+32%
Free Cash Flow Per Share---0.228-0.211-7%-0.172-24%-0.219-4%-0.262+15%-0.335+47%
Free Cash Flow To Equity Per Share---0.161-0.101-38%-0.120-26%-0.054-66%0.067-341%0.060-370%
Gross Profit Margin--0.8681.323-34%1.519-43%1.473-41%2.379-64%2.259-62%
Intrinsic Value_10Y_max--1.706----------
Intrinsic Value_10Y_min---4.009----------
Intrinsic Value_1Y_max---0.725----------
Intrinsic Value_1Y_min---1.187----------
Intrinsic Value_3Y_max---1.495----------
Intrinsic Value_3Y_min---2.907----------
Intrinsic Value_5Y_max---1.442----------
Intrinsic Value_5Y_min---3.892----------
Market Cap3198910.000-6%3402477.0005939939.655-43%2196778.740+55%4655819.632-27%4385327.557-22%8650536.044-61%
Net Profit Margin--3.3220.410+710%-0.935+128%-0.594+118%-0.700+121%-1.066+132%
Operating Margin---0.559-0.359-36%-0.513-8%-0.333-40%-0.561+0%-1.004+80%
Operating Ratio--1.7741.639+8%1.362+30%1.510+17%1.667+6%2.054-14%
Pb Ratio0.519-6%0.552-10.910+2077%1.261-56%-3.023+648%-1.364+347%1.025-46%
Pe Ratio0.104-6%0.111-0.866+881%-0.191+272%-0.516+565%-0.689+721%-0.854+870%
Price Per Share0.550-6%0.5851.021-43%0.378+55%0.800-27%0.754-22%1.487-61%
Price To Free Cash Flow Ratio-0.604+6%-0.642-1.702+165%-0.986+53%-1.238+93%-1.015+58%-0.656+2%
Price To Total Gains Ratio0.508-6%0.540-4.135+865%-3.901+822%-3.554+758%-1.283+337%-0.232+143%
Quick Ratio--2.8881.032+180%0.920+214%1.149+151%2.102+37%1.964+47%
Return On Assets--0.777-0.073+109%-0.361+146%-0.226+129%-0.191+125%-0.251+132%
Return On Equity--1.2440.028+4298%-5.512+543%-1.955+257%-1.452+217%-1.872+251%
Total Gains Per Share--1.0820.258+319%-0.375+135%-0.166+115%0.056+1832%0.017+6168%
Usd Book Value--6167000.0001623250.000+280%4768500.000+29%6211666.667-1%8059800.000-23%5253550.000+17%
Usd Book Value Change Per Share--1.0820.258+319%-0.375+135%-0.166+115%0.056+1832%0.017+6168%
Usd Book Value Per Share--1.0600.279+280%0.820+29%1.068-1%1.386-23%0.903+17%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--8164477.0004787439.655+71%-637721.260+108%2554819.632+220%4599377.557+78%7497086.044+9%
Usd Eps--1.3190.157+738%-0.564+143%-0.392+130%-0.374+128%-0.417+132%
Usd Free Cash Flow---1324000.000-1230000.000-7%-1001500.000-24%-1272250.000-4%-1523700.000+15%-1946250.000+47%
Usd Free Cash Flow Per Share---0.228-0.211-7%-0.172-24%-0.219-4%-0.262+15%-0.335+47%
Usd Free Cash Flow To Equity Per Share---0.161-0.101-38%-0.120-26%-0.054-66%0.067-341%0.060-370%
Usd Market Cap3198910.000-6%3402477.0005939939.655-43%2196778.740+55%4655819.632-27%4385327.557-22%8650536.044-61%
Usd Price Per Share0.550-6%0.5851.021-43%0.378+55%0.800-27%0.754-22%1.487-61%
Usd Profit--7670000.000915250.000+738%-3277750.000+143%-2278583.250+130%-2173499.950+128%-2424274.975+132%
Usd Revenue--2309000.0002364750.000-2%3555750.000-35%3110000.000-26%2820600.000-18%2784525.000-17%
Usd Total Gains Per Share--1.0820.258+319%-0.375+135%-0.166+115%0.056+1832%0.017+6168%
 EOD+3 -5MRQTTM+23 -15YOY+25 -133Y+19 -195Y+23 -1510Y+28 -10

3.3 Fundamental Score

Let's check the fundamental score of NovaBay Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.104
Price to Book Ratio (EOD)Between0-10.519
Net Profit Margin (MRQ)Greater than03.322
Operating Margin (MRQ)Greater than0-0.559
Quick Ratio (MRQ)Greater than12.888
Current Ratio (MRQ)Greater than12.947
Debt to Asset Ratio (MRQ)Less than10.375
Debt to Equity Ratio (MRQ)Less than10.601
Return on Equity (MRQ)Greater than0.151.244
Return on Assets (MRQ)Greater than0.050.777
Total9/10 (90.0%)

3.4 Technical Score

Let's check the technical score of NovaBay Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.715
Ma 20Greater thanMa 500.574
Ma 50Greater thanMa 1000.574
Ma 100Greater thanMa 2000.615
OpenGreater thanClose0.550
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About NovaBay Pharmaceuticals Inc

NovaBay Pharmaceuticals, Inc. does not have significant operations. Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Fundamental data was last updated by Penke on 2025-05-18 07:28:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Novabay earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Novabay to the Biotechnology industry mean.
  • A Net Profit Margin of 332.2% means that $3.32 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NovaBay Pharmaceuticals Inc:

  • The MRQ is 332.2%. The company is making a huge profit. +2
  • The TTM is 41.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ332.2%TTM41.0%+291.2%
TTM41.0%YOY-93.5%+134.5%
TTM41.0%5Y-70.0%+111.0%
5Y-70.0%10Y-106.6%+36.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ332.2%-94.6%+426.8%
TTM41.0%-165.1%+206.1%
YOY-93.5%-194.4%+100.9%
3Y-59.4%-248.5%+189.1%
5Y-70.0%-341.8%+271.8%
10Y-106.6%-468.5%+361.9%
4.3.1.2. Return on Assets

Shows how efficient Novabay is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Novabay to the Biotechnology industry mean.
  • 77.7% Return on Assets means that Novabay generated $0.78 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NovaBay Pharmaceuticals Inc:

  • The MRQ is 77.7%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is -7.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ77.7%TTM-7.3%+85.0%
TTM-7.3%YOY-36.1%+28.7%
TTM-7.3%5Y-19.1%+11.8%
5Y-19.1%10Y-25.1%+6.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ77.7%-11.2%+88.9%
TTM-7.3%-11.2%+3.9%
YOY-36.1%-11.0%-25.1%
3Y-22.6%-11.6%-11.0%
5Y-19.1%-11.9%-7.2%
10Y-25.1%-13.9%-11.2%
4.3.1.3. Return on Equity

Shows how efficient Novabay is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Novabay to the Biotechnology industry mean.
  • 124.4% Return on Equity means Novabay generated $1.24 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NovaBay Pharmaceuticals Inc:

  • The MRQ is 124.4%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 2.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ124.4%TTM2.8%+121.5%
TTM2.8%YOY-551.2%+554.0%
TTM2.8%5Y-145.2%+148.0%
5Y-145.2%10Y-187.2%+42.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ124.4%-13.2%+137.6%
TTM2.8%-14.2%+17.0%
YOY-551.2%-14.6%-536.6%
3Y-195.5%-16.9%-178.6%
5Y-145.2%-17.4%-127.8%
10Y-187.2%-19.6%-167.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of NovaBay Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Novabay is operating .

  • Measures how much profit Novabay makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Novabay to the Biotechnology industry mean.
  • An Operating Margin of -55.9% means the company generated $-0.56  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NovaBay Pharmaceuticals Inc:

  • The MRQ is -55.9%. The company is operating very inefficient. -2
  • The TTM is -35.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-55.9%TTM-35.9%-19.9%
TTM-35.9%YOY-51.3%+15.4%
TTM-35.9%5Y-56.1%+20.1%
5Y-56.1%10Y-100.4%+44.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-55.9%-199.7%+143.8%
TTM-35.9%-274.4%+238.5%
YOY-51.3%-208.4%+157.1%
3Y-33.3%-220.1%+186.8%
5Y-56.1%-345.5%+289.4%
10Y-100.4%-440.0%+339.6%
4.3.2.2. Operating Ratio

Measures how efficient Novabay is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.77 means that the operating costs are $1.77 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of NovaBay Pharmaceuticals Inc:

  • The MRQ is 1.774. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.639. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.774TTM1.639+0.135
TTM1.639YOY1.362+0.277
TTM1.6395Y1.667-0.028
5Y1.66710Y2.054-0.387
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7742.121-0.347
TTM1.6392.810-1.171
YOY1.3623.013-1.651
3Y1.5103.620-2.110
5Y1.6674.729-3.062
10Y2.0546.319-4.265
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of NovaBay Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Novabay is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.95 means the company has $2.95 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of NovaBay Pharmaceuticals Inc:

  • The MRQ is 2.947. The company is able to pay all its short-term debts. +1
  • The TTM is 1.350. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ2.947TTM1.350+1.597
TTM1.350YOY1.558-0.208
TTM1.3505Y2.758-1.408
5Y2.75810Y2.520+0.237
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9473.609-0.662
TTM1.3503.858-2.508
YOY1.5584.210-2.652
3Y1.8324.687-2.855
5Y2.7585.817-3.059
10Y2.5206.151-3.631
4.4.3.2. Quick Ratio

Measures if Novabay is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Novabay to the Biotechnology industry mean.
  • A Quick Ratio of 2.89 means the company can pay off $2.89 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NovaBay Pharmaceuticals Inc:

  • The MRQ is 2.888. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.032. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ2.888TTM1.032+1.855
TTM1.032YOY0.920+0.112
TTM1.0325Y2.102-1.069
5Y2.10210Y1.964+0.138
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8882.869+0.019
TTM1.0323.363-2.331
YOY0.9203.951-3.031
3Y1.1494.457-3.308
5Y2.1025.846-3.744
10Y1.9646.543-4.579
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of NovaBay Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Novabay assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Novabay to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.38 means that Novabay assets are financed with 37.5% credit (debt) and the remaining percentage (100% - 37.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of NovaBay Pharmaceuticals Inc:

  • The MRQ is 0.375. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.823. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.375TTM0.823-0.448
TTM0.823YOY0.630+0.193
TTM0.8235Y0.501+0.322
5Y0.50110Y0.689-0.188
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3750.336+0.039
TTM0.8230.349+0.474
YOY0.6300.335+0.295
3Y0.6020.334+0.268
5Y0.5010.352+0.149
10Y0.6890.380+0.309
4.5.4.2. Debt to Equity Ratio

Measures if Novabay is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Novabay to the Biotechnology industry mean.
  • A Debt to Equity ratio of 60.1% means that company has $0.60 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NovaBay Pharmaceuticals Inc:

  • The MRQ is 0.601. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.804. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.601TTM0.804-0.204
TTM0.804YOY8.976-8.171
TTM0.8045Y2.843-2.039
5Y2.84310Y3.780-0.937
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6010.398+0.203
TTM0.8040.430+0.374
YOY8.9760.416+8.560
3Y3.4440.464+2.980
5Y2.8430.461+2.382
10Y3.7800.510+3.270
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Novabay generates.

  • Above 15 is considered overpriced but always compare Novabay to the Biotechnology industry mean.
  • A PE ratio of 0.11 means the investor is paying $0.11 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NovaBay Pharmaceuticals Inc:

  • The EOD is 0.104. Based on the earnings, the company is cheap. +2
  • The MRQ is 0.111. Based on the earnings, the company is cheap. +2
  • The TTM is -0.866. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.104MRQ0.111-0.007
MRQ0.111TTM-0.866+0.977
TTM-0.866YOY-0.191-0.675
TTM-0.8665Y-0.689-0.178
5Y-0.68910Y-0.854+0.165
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.104-1.922+2.026
MRQ0.111-2.104+2.215
TTM-0.866-2.676+1.810
YOY-0.191-3.493+3.302
3Y-0.516-3.882+3.366
5Y-0.689-6.202+5.513
10Y-0.854-6.657+5.803
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NovaBay Pharmaceuticals Inc:

  • The EOD is -0.604. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.642. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.702. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.604MRQ-0.642+0.038
MRQ-0.642TTM-1.702+1.060
TTM-1.702YOY-0.986-0.717
TTM-1.7025Y-1.015-0.687
5Y-1.01510Y-0.656-0.359
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.604-2.673+2.069
MRQ-0.642-2.705+2.063
TTM-1.702-3.568+1.866
YOY-0.986-4.283+3.297
3Y-1.238-5.235+3.997
5Y-1.015-8.073+7.058
10Y-0.656-9.113+8.457
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Novabay is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.55 means the investor is paying $0.55 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of NovaBay Pharmaceuticals Inc:

  • The EOD is 0.519. Based on the equity, the company is cheap. +2
  • The MRQ is 0.552. Based on the equity, the company is cheap. +2
  • The TTM is -10.910. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.519MRQ0.552-0.033
MRQ0.552TTM-10.910+11.462
TTM-10.910YOY1.261-12.171
TTM-10.9105Y-1.364-9.545
5Y-1.36410Y1.025-2.389
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5191.854-1.335
MRQ0.5521.941-1.389
TTM-10.9102.201-13.111
YOY1.2612.477-1.216
3Y-3.0232.667-5.690
5Y-1.3643.606-4.970
10Y1.0254.284-3.259
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of NovaBay Pharmaceuticals Inc.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Net Debt  6006591,259-773486-351135-7,477-7,342
Income before Tax  -3,0901,505-1,585-632-2,217894-1,3238,9937,670
Net Income  -3,2141,629-1,585373-1,2120-1,2128,8827,670
Total Other Income Expense Net -654122-532-624-1,1561,155-111,00111,000



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets9,872
Total Liabilities3,705
Total Stockholder Equity6,167
 As reported
Total Liabilities 3,705
Total Stockholder Equity+ 6,167
Total Assets = 9,872

Assets

Total Assets9,872
Total Current Assets9,038
Long-term Assets834
Total Current Assets
Cash And Cash Equivalents 8,467
Net Receivables 389
Other Current Assets 571
Total Current Assets  (as reported)9,038
Total Current Assets  (calculated)9,427
+/- 389
Long-term Assets
Property Plant Equipment 355
Long-term Assets Other 479
Long-term Assets  (as reported)834
Long-term Assets  (calculated)834
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,067
Long-term Liabilities638
Total Stockholder Equity6,167
Total Current Liabilities
Short-term Debt 487
Accounts payable 800
Other Current Liabilities 980
Total Current Liabilities  (as reported)3,067
Total Current Liabilities  (calculated)2,267
+/- 800
Long-term Liabilities
Long-term Liabilities  (as reported)638
Long-term Liabilities  (calculated)0
+/- 638
Total Stockholder Equity
Common Stock58
Retained Earnings -175,787
Other Stockholders Equity 181,896
Total Stockholder Equity (as reported)6,167
Total Stockholder Equity (calculated)6,167
+/-0
Other
Cash and Short Term Investments 8,467
Common Stock Shares Outstanding 5,308
Current Deferred Revenue488
Liabilities and Stockholders Equity 9,872
Net Debt -7,342
Net Working Capital 5,971
Short Long Term Debt Total 1,125



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-31
> Total Assets 
0
0
0
3,562
0
0
0
11,866
11,483
9,320
8,157
23,922
22,275
19,128
17,424
13,969
14,958
13,029
15,241
17,523
16,167
13,671
13,114
15,516
14,667
15,036
18,301
15,963
14,042
12,074
13,670
19,235
15,416
12,827
12,245
15,650
17,185
13,513
11,043
7,537
8,155
10,174
6,690
5,077
4,931
7,005
15,141
15,381
12,682
12,070
11,056
10,079
13,823
11,705
10,365
9,361
9,720
9,870
14,603
11,220
9,475
13,272
17,082
15,238
14,072
13,603
12,239
23,978
24,794
21,544
22,376
16,399
14,825
16,008
12,852
9,034
5,357
3,925
3,877
3,423
9,872
9,8723,4233,8773,9255,3579,03412,85216,00814,82516,39922,37621,54424,79423,97812,23913,60314,07215,23817,08213,2729,47511,22014,6039,8709,7209,36110,36511,70513,82310,07911,05612,07012,68215,38115,1417,0054,9315,0776,69010,1748,1557,53711,04313,51317,18515,65012,24512,82715,41619,23513,67012,07414,04215,96318,30115,03614,66715,51613,11413,67116,16717,52315,24113,02914,95813,96917,42419,12822,27523,9228,1579,32011,48311,8660003,562000
   > Total Current Assets 
0
0
0
3,295
0
0
0
11,312
10,560
8,397
7,245
22,772
20,820
17,628
15,975
12,513
13,558
11,454
13,457
15,606
14,206
11,711
11,170
13,754
12,931
13,413
16,785
14,558
12,789
10,888
12,516
18,281
14,534
11,992
11,484
14,791
16,383
12,879
10,418
6,952
7,596
9,646
6,177
4,527
4,561
6,574
14,420
14,471
11,531
10,967
9,938
8,995
12,791
10,772
9,528
8,608
7,115
7,496
12,498
9,381
7,874
11,908
16,012
14,242
13,146
12,772
11,497
13,170
12,478
9,459
10,613
11,332
9,894
11,216
8,214
7,154
3,591
2,253
2,279
1,935
9,038
9,0381,9352,2792,2533,5917,1548,21411,2169,89411,33210,6139,45912,47813,17011,49712,77213,14614,24216,01211,9087,8749,38112,4987,4967,1158,6089,52810,77212,7918,9959,93810,96711,53114,47114,4206,5744,5614,5276,1779,6467,5966,95210,41812,87916,38314,79111,48411,99214,53418,28112,51610,88812,78914,55816,78513,41312,93113,75411,17011,71114,20615,60613,45711,45413,55812,51315,97517,62820,82022,7727,2458,39710,56011,3120003,295000
       Cash And Cash Equivalents 
0
0
0
2,208
0
0
0
4,903
3,861
1,871
689
10,941
11,309
9,998
11,739
12,099
10,243
8,000
10,630
10,992
12,890
10,344
9,415
11,534
11,869
7,973
12,430
8,428
6,121
4,653
7,219
12,735
8,387
6,594
6,934
10,500
10,316
7,757
7,884
5,429
5,598
7,208
3,383
2,385
1,430
3,495
9,430
9,512
7,399
5,722
6,076
3,199
8,336
6,833
5,207
3,183
2,932
3,668
9,020
6,937
5,708
8,775
13,413
11,952
10,508
10,294
9,028
7,504
5,641
3,931
3,868
5,362
3,746
4,414
3,472
3,130
1,823
751
776
430
8,467
8,4674307767511,8233,1303,4724,4143,7465,3623,8683,9315,6417,5049,02810,29410,50811,95213,4138,7755,7086,9379,0203,6682,9323,1835,2076,8338,3363,1996,0765,7227,3999,5129,4303,4951,4302,3853,3837,2085,5985,4297,8847,75710,31610,5006,9346,5948,38712,7357,2194,6536,1218,42812,4307,97311,86911,5349,41510,34412,89010,99210,6308,00010,24312,09911,7399,99811,30910,9416891,8713,8614,9030002,208000
       Short-term Investments 
0
0
0
1,004
0
0
0
6,183
6,192
6,182
6,192
11,412
8,899
6,905
3,463
0
2,631
2,685
1,050
300
854
851
1,383
1,272
750
1,288
2,241
5,710
5,232
5,720
4,663
4,135
4,805
4,811
3,885
2,553
4,858
3,808
1,251
0
0
0
0
0
0
293
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000002930000001,2513,8084,8582,5533,8854,8114,8054,1354,6635,7205,2325,7102,2411,2887501,2721,3838518543001,0502,6852,63103,4636,9058,89911,4126,1926,1826,1926,1830001,004000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,037
3,750
51
29
0
500
500
3,566
1,825
3
1,009
9
126
943
916
112
272
784
260
440
364
273
283
389
543
536
1,497
1,490
2,079
2,120
2,331
3,733
2,341
3,715
2,350
2,125
2,749
3,493
2,430
1,649
1,588
1,066
952
1,391
1,119
1,106
1,359
1,232
843
1,668
2,300
1,098
2,133
1,973
1,835
2,623
916
759
734
547
704
389
389
3893897045477347599162,6231,8351,9732,1331,0982,3001,6688431,2321,3591,1061,1191,3919521,0661,5881,6492,4303,4932,7492,1252,3503,7152,3413,7332,3312,1202,0791,4901,49753654338928327336444026078427211291694312691,00931,8253,566500500029513,7501,037000000000000000000
       Other Current Assets 
0
0
0
83
0
0
0
226
507
344
364
419
612
725
773
414
684
769
740
564
411
487
372
448
312
586
289
417
427
506
508
445
730
854
330
884
794
656
514
729
1,223
597
668
261
433
474
1,827
1,966
1,036
840
922
1,577
1,626
1,497
1,182
1,652
1,451
1,515
1,052
1,090
662
1,116
695
576
429
564
657
778
752
629
544
113
516
519
333
388
371
255
326
110
571
5711103262553713883335195161135446297527786575644295766951,1166621,0901,0521,5151,4511,6521,1821,4971,6261,5779228401,0361,9661,8274744332616685971,22372951465679488433085473044550850642741728958631244837248741156474076968441477372561241936434450722600083000
   > Long-term Assets 
0
0
0
267
0
0
0
554
923
923
912
1,150
1,455
1,500
1,449
1,456
1,400
1,575
1,784
1,917
1,961
1,960
1,944
1,762
1,736
1,623
1,516
1,405
1,253
1,186
1,154
954
882
835
761
859
802
634
625
585
559
528
513
550
370
431
721
910
1,151
1,103
1,118
1,084
1,032
933
837
753
2,605
2,374
2,105
1,839
1,601
1,364
1,070
996
926
831
741
10,808
12,316
12,085
11,763
5,067
4,931
4,792
4,638
1,880
1,766
1,672
1,598
1,488
834
8341,4881,5981,6721,7661,8804,6384,7924,9315,06711,76312,08512,31610,8087418319269961,0701,3641,6011,8392,1052,3742,6057538379331,0321,0841,1181,1031,1519107214313705505135285595856256348028597618358829541,1541,1861,2531,4051,5161,6231,7361,7621,9441,9601,9611,9171,7841,5751,4001,4561,4491,5001,4551,150912923923554000267000
       Property Plant Equipment 
0
0
0
267
0
0
0
554
923
923
912
1,150
1,455
1,500
1,449
1,456
1,400
1,575
1,784
1,812
1,736
1,736
1,663
1,588
1,598
1,475
1,372
1,270
1,148
1,069
1,037
891
819
761
687
718
658
488
478
436
408
375
359
395
370
366
282
371
421
462
492
471
435
351
271
201
2,063
1,832
1,563
1,362
1,125
887
594
520
450
356
266
604
2,518
2,383
2,154
1,950
1,863
1,744
1,623
1,383
1,289
1,196
1,103
1,008
355
3551,0081,1031,1961,2891,3831,6231,7441,8631,9502,1542,3832,5186042663564505205948871,1251,3621,5631,8322,0632012713514354714924624213712823663703953593754084364784886587186877618198911,0371,0691,1481,2701,3721,4751,5981,5881,6631,7361,7361,8121,7841,5751,4001,4561,4491,5001,4551,150912923923554000267000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,528
4,528
4,528
4,528
348
348
348
348
0
0
0
0
0
0
0000003483483483484,5284,5284,5284,5280000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100
0
0
100
5,200
5,109
5,018
4,928
2,280
2,242
2,204
2,166
0
0
0
0
0
0
0000002,1662,2042,2422,2804,9285,0185,1095,20010000100000000000000000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
105
225
224
281
174
138
148
144
135
105
117
117
63
63
74
74
141
144
146
147
149
151
153
154
155
0
65
439
539
730
641
626
613
597
582
566
552
542
542
542
477
476
477
476
912
476
475
1
476
161
156
153
489
478
496
0
0
0
0
0
0
-42,483
-42,4830000004964784891531561614761475476912476477476477542542542552566582597613626641730539439650155154153151149147146144141747463631171171051351441481381742812242251050000000000000000000
> Total Liabilities 
0
0
0
310
0
0
0
10,053
10,796
10,243
10,749
9,602
10,346
9,247
8,794
6,624
7,457
5,573
5,654
4,178
3,981
2,357
3,136
5,026
5,725
5,399
5,358
6,619
6,674
6,461
6,226
5,186
5,079
5,617
6,823
7,134
5,349
4,293
5,353
5,689
6,006
5,270
6,463
10,175
12,230
9,472
8,423
8,280
8,326
8,861
9,224
7,485
4,952
4,276
4,306
4,407
9,380
8,201
11,680
10,247
9,824
12,289
3,200
2,920
3,089
2,394
2,875
13,807
7,048
5,799
8,592
5,845
5,935
7,445
5,815
5,720
5,197
4,542
2,805
3,552
3,705
3,7053,5522,8054,5425,1975,7205,8157,4455,9355,8458,5925,7997,04813,8072,8752,3943,0892,9203,20012,2899,82410,24711,6808,2019,3804,4074,3064,2764,9527,4859,2248,8618,3268,2808,4239,47212,23010,1756,4635,2706,0065,6895,3534,2935,3497,1346,8235,6175,0795,1866,2266,4616,6746,6195,3585,3995,7255,0263,1362,3573,9814,1785,6545,5737,4576,6248,7949,24710,3469,60210,74910,24310,79610,053000310000
   > Total Current Liabilities 
0
0
0
310
0
0
0
3,386
4,677
4,200
5,425
4,578
5,890
5,379
5,672
4,480
5,693
4,685
5,436
4,038
3,939
2,357
3,040
2,723
3,732
3,715
3,985
2,838
2,934
3,744
4,032
3,173
2,474
2,789
3,062
3,627
2,282
2,017
2,353
3,345
3,698
2,761
4,254
4,633
4,028
4,368
3,728
4,323
4,302
4,735
5,262
4,979
3,218
3,056
3,377
3,847
5,414
3,352
6,252
5,687
5,483
4,301
3,003
2,833
3,080
2,389
2,874
3,442
4,784
3,657
3,710
4,257
4,423
6,066
4,571
4,278
3,924
3,610
1,984
2,843
3,067
3,0672,8431,9843,6103,9244,2784,5716,0664,4234,2573,7103,6574,7843,4422,8742,3893,0802,8333,0034,3015,4835,6876,2523,3525,4143,8473,3773,0563,2184,9795,2624,7354,3024,3233,7284,3684,0284,6334,2542,7613,6983,3452,3532,0172,2823,6273,0622,7892,4743,1734,0323,7442,9342,8383,9853,7153,7322,7233,0402,3573,9394,0385,4364,6855,6934,4805,6725,3795,8904,5785,4254,2004,6773,386000310000
       Short-term Debt 
0
0
0
0
0
0
0
0
34
165
170
256
314
388
397
408
415
416
415
371
330
271
168
106
42
0
631
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,655
0
0
0
0
0
0
0
0
0
0
0
0
2,092
2,130
4,103
3,541
2,978
1,141
504
832
792
596
390
505
930
940
890
453
932
2,137
2,240
2,127
1,382
1,460
441
0
487
48704411,4601,3822,1272,2402,1379324538909409305053905967928325041,1412,9783,5414,1032,1302,0920000000000001,65500000000000000006310421061682713303714154164154083973883142561701653400000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,655
0
0
0
0
0
0
0
0
0
0
0
0
1,019
0
3,045
2,611
2,204
522
104
0
0
0
0
105
0
0
0
0
0
1,185
1,270
1,137
1,007
696
51
565
0
0565516961,0071,1371,2701,1850000010500001045222,2042,6113,04501,0190000000000001,6550000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
137
0
0
0
365
436
162
339
142
664
558
457
406
367
533
314
272
227
428
291
406
346
448
320
472
439
901
1,051
455
539
611
1,013
1,674
487
520
918
1,865
2,178
1,777
2,870
2,483
1,820
860
387
455
798
908
356
466
301
329
564
551
462
356
503
331
602
1,291
796
302
833
208
1,354
1,045
1,556
930
1,097
1,080
1,148
1,481
947
1,130
1,117
1,235
396
623
800
8006233961,2351,1171,1309471,4811,1481,0801,0979301,5561,0451,3542088333027961,2916023315033564625515643293014663569087984553878601,8202,4832,8701,7772,1781,8659185204871,6741,0136115394551,051901439472320448346406291428227272314533367406457558664142339162436365000137000
       Other Current Liabilities 
0
0
0
173
0
0
0
521
1,032
1,171
1,539
1,141
1,238
1,424
1,350
1,166
1,075
636
965
1,228
681
1,041
1,130
726
1,033
961
1,852
1,061
1,161
1,306
1,572
1,497
1,178
1,708
1,842
1,616
1,595
1,301
1,176
1,055
1,095
764
1,006
1,980
2,019
1,915
1,880
1,801
1,831
1,655
2,419
1,672
2,855
2,665
2,751
3,154
1,044
866
1,646
1,815
1,344
1,322
1,703
1,699
921
863
706
763
371
96
-252
917
556
631
1,384
1,021
1,425
915
1,147
0
980
98001,1479151,4251,0211,384631556917-252963717637068639211,6991,7031,3221,3441,8151,6468661,0443,1542,7512,6652,8551,6722,4191,6551,8311,8011,8801,9152,0191,9801,0067641,0951,0551,1761,3011,5951,6161,8421,7081,1781,4971,5721,3061,1611,0611,8529611,0337261,1301,0416811,2289656361,0751,1661,3501,4241,2381,1411,5391,1711,032521000173000
   > Long-term Liabilities 
0
0
0
0
0
0
0
6,667
6,119
6,043
5,324
5,024
4,456
3,868
3,122
2,144
1,764
888
218
140
42
0
96
2,303
1,993
1,684
1,373
3,781
3,740
2,717
2,194
2,013
2,605
2,828
3,761
3,507
3,067
2,276
3,000
2,344
2,308
2,509
2,209
5,542
8,202
5,104
4,695
3,957
4,024
4,126
3,962
2,506
1,734
1,220
929
560
3,966
4,849
5,428
4,560
4,341
7,988
197
87
9
5
1
10,365
2,264
2,142
4,882
1,588
1,512
1,379
1,244
1,442
1,273
932
821
709
638
6387098219321,2731,4421,2441,3791,5121,5884,8822,1422,26410,365159871977,9884,3414,5605,4284,8493,9665609291,2201,7342,5063,9624,1264,0243,9574,6955,1048,2025,5422,2092,5092,3082,3443,0002,2763,0673,5073,7612,8282,6052,0132,1942,7173,7403,7811,3731,6841,9932,303960421402188881,7642,1443,1223,8684,4565,0245,3246,0436,1196,6670000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,227
1,654
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000001,6541,22700000000000000000000000000000000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
584
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000005840000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
6,667
0
5,626
4,951
4,478
3,839
3,181
2,539
1,667
1,392
617
50
0
0
0
96
2,303
1,993
1,684
1,373
3,781
3,740
2,717
2,194
2,013
2,605
2,828
3,761
3,507
3,067
2,276
3,000
2,344
2,308
2,509
2,209
3,887
5,139
4,580
4,695
3,957
4,024
4,126
3,962
2,506
1,734
1,220
929
560
807
1,196
4,217
4,055
3,935
7,685
0
0
0
0
0
10,119
342
342
3,169
0
0
0
0
0
0
0
0
0
0
00000000003,16934234210,119000007,6853,9354,0554,2171,1968075609291,2201,7342,5063,9624,1264,0243,9574,6954,5805,1393,8872,2092,5092,3082,3443,0002,2763,0673,5073,7612,8282,6052,0132,1942,7173,7403,7811,3731,6841,9932,30396000506171,3921,6672,5393,1813,8394,4784,9515,62606,6670000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,684
1,373
1,060
984
589
275
731
803
1,130
1,197
1,670
1,750
1,756
2,376
2,171
2,169
2,370
2,209
2,437
3,304
189
2,161
2,313
2,121
300
1,855
802
0
0
213
0
427
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000004270213008021,8553002,1212,3132,1611893,3042,4372,2092,3702,1692,1712,3761,7561,7501,6701,1971,1308037312755899841,0601,3731,6840000000000000000000000000
> Total Stockholder Equity
0
0
0
3,252
0
0
0
1,813
687
-923
-2,592
14,320
11,929
9,881
8,630
7,345
7,501
7,456
9,587
13,345
12,186
11,314
9,978
10,490
8,942
9,637
12,943
9,344
7,368
5,613
7,444
14,049
10,337
7,210
5,422
8,516
11,836
9,220
5,690
1,848
2,149
4,904
227
-5,098
-7,299
-2,467
6,718
7,101
4,356
3,209
1,832
2,594
8,871
7,429
6,059
4,954
340
1,669
2,923
973
-349
983
13,882
12,318
10,983
11,209
9,364
10,171
17,746
15,745
13,784
10,554
8,890
8,563
7,037
3,314
160
-617
1,072
-129
6,167
6,167-1291,072-6171603,3147,0378,5638,89010,55413,78415,74517,74610,1719,36411,20910,98312,31813,882983-3499732,9231,6693404,9546,0597,4298,8712,5941,8323,2094,3567,1016,718-2,467-7,299-5,0982274,9042,1491,8485,6909,22011,8368,5165,4227,21010,33714,0497,4445,6137,3689,34412,9439,6378,94210,4909,97811,31412,18613,3459,5877,4567,5017,3458,6309,88111,92914,320-2,592-9236871,8130003,252000
   Common Stock
0
0
0
50
0
0
0
63
130
65
66
212
212
214
214
215
217
220
233
233
233
233
233
234
235
235
283
286
288
289
297
369
369
374
387
446
507
508
511
516
611
736
746
35
51
92
149
153
153
153
154
154
171
171
171
171
171
207
252
279
282
346
417
418
418
447
450
478
514
535
650
652
652
673
65
112
320
13
49
0
58
58049133201126567365265265053551447845044741841841734628227925220717117117117117115415415315315314992513574673661151651150850744638737436936929728928828628323523523423323323323323322021721521421421221266651306300050000
   Retained Earnings Total Equity000000000000000-139,440-137,581-136,063-134,309-131,088-126,606-125,024-122,338-122,056-119,526-114,981-113,713-112,175-110,585-111,074-111,867-109,421-107,682-103,671-102,023-98,287-95,598-90,520-86,316-81,074-76,187-71,547-67,079-62,861-59,918-56,353-52,216-48,368-44,320-40,311-37,961-38,041-35,815-33,284-29,656-29,7620000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-4
0
0
0
12
23
13
23
-3
13
24
31
-638
-8
-3
-906
-1,011
-2
-5
-3
-14
-1,438
-4
-9
-44
-42
-62
-29
-13
-11
-19
-13
-15
-13
-13
-9
-1,540
-76,000
0
0
-1,702
-1,742
-1,769
-396
-149
-166
-184
-203
-243
-284
-370
-462
-509
-526
-542
-559
-560
-573
-580
-592
0
0
0
0
-680
0
0
0
0
0
-449
-302
-112
-44
-6
-6
0
0
00-6-6-44-112-302-44900000-6800000-592-580-573-560-559-542-526-509-462-370-284-243-203-184-166-149-396-1,769-1,742-1,70200-76,000-1,540-9-13-13-15-13-19-11-13-29-62-42-44-9-4-1,438-14-3-5-2-1,011-906-3-8-638312413-323132312000-4000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
39,168
42,325
42,386
42,937
43,427
45,137
54,004
54,299
55,223
57,264
64,438
71,260
71,586
72,267
72,879
77,725
85,242
85,797
85,387
88,248
95,728
108,592
110,619
111,885
112,477
113,545
113,514
119,285
119,433
119,601
119,764
120,484
123,518
125,009
125,718
125,975
131,725
147,774
147,963
148,146
150,202
150,643
150,900
158,621
158,793
162,510
165,081
165,156
169,689
0
0
0
0
0
0
0
0000000169,689165,156165,081162,510158,793158,621150,900150,643150,202148,146147,963147,774131,725125,975125,718125,009123,518120,484119,764119,601119,433119,285113,514113,545112,477111,885110,619108,59295,72888,24885,38785,79785,24277,72572,87972,26771,58671,26064,43857,26455,22354,29954,00445,13743,42742,93742,38642,32539,1680000000000000000000000000
   Treasury Stock000000000000000000000000000000000000-7,29900000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
10,819
0
0
0
14,620
14,309
14,331
14,273
32,585
32,856
33,206
33,437
33,718
34,199
34,434
36,661
37,003
37,475
37,805
38,108
38,469
38,894
39,168
42,325
42,386
42,937
43,427
45,137
54,004
54,299
55,223
57,264
64,438
71,260
71,586
72,267
73,374
77,725
85,242
85,797
85,387
88,248
97,497
108,592
110,619
111,885
112,477
113,545
113,514
119,285
119,433
119,601
119,764
120,826
123,518
124,425
125,718
125,975
131,725
147,774
147,963
148,146
150,202
150,643
150,900
158,621
158,793
162,510
165,081
165,156
169,689
170,675
176,101
176,798
179,392
183,262
0
181,896
181,8960183,262179,392176,798176,101170,675169,689165,156165,081162,510158,793158,621150,900150,643150,202148,146147,963147,774131,725125,975125,718124,425123,518120,826119,764119,601119,433119,285113,514113,545112,477111,885110,619108,59297,49788,24885,38785,79785,24277,72573,37472,26771,58671,26064,43857,26455,22354,29954,00445,13743,42742,93742,38642,32539,16838,89438,46938,10837,80537,47537,00336,66134,43434,19933,71833,43733,20632,85632,58514,27314,33114,30914,62000010,819000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue9,781
Cost of Revenue-3,300
Gross Profit6,4816,481
 
Operating Income (+$)
Gross Profit6,481
Operating Expense-12,320
Operating Income-5,839-5,839
 
Operating Expense (+$)
Research Development42
Selling General Administrative7,379
Selling And Marketing Expenses4,034
Operating Expense12,32011,455
 
Net Interest Income (+$)
Interest Income0
Interest Expense-904
Other Finance Cost-0
Net Interest Income-904
 
Pretax Income (+$)
Operating Income-5,839
Net Interest Income-904
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-7,210-4,468
EBIT - interestExpense = -7,210
-7,223
-6,319
Interest Expense904
Earnings Before Interest and Taxes (EBIT)-6,306-6,306
Earnings Before Interest and Taxes (EBITDA)-5,925
 
After tax Income (+$)
Income Before Tax-7,210
Tax Provision-0
Net Income From Continuing Ops-7,210-7,210
Net Income-7,223
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses14,721
Total Other Income/Expenses Net-1,371904
 

Technical Analysis of Novabay
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Novabay. The general trend of Novabay is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Novabay's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Novabay Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of NovaBay Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.61 < 0.62 < 0.635.

The bearish price targets are: 0.51 > 0.46 > 0.44.

Know someone who trades $NBY? Share this with them.👇

NovaBay Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of NovaBay Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

NovaBay Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of NovaBay Pharmaceuticals Inc. The current macd is -0.00558942.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Novabay price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Novabay. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Novabay price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
NovaBay Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartNovaBay Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of NovaBay Pharmaceuticals Inc. The current adx is 18.28.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Novabay shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
NovaBay Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of NovaBay Pharmaceuticals Inc. The current sar is 0.51698687.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
NovaBay Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of NovaBay Pharmaceuticals Inc. The current rsi is 40.72. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
NovaBay Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartNovaBay Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of NovaBay Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Novabay price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
NovaBay Pharmaceuticals Inc Daily Stochastic Oscillator ChartNovaBay Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of NovaBay Pharmaceuticals Inc. The current cci is -119.09475453.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
NovaBay Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartNovaBay Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of NovaBay Pharmaceuticals Inc. The current cmo is -29.59615643.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
NovaBay Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartNovaBay Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of NovaBay Pharmaceuticals Inc. The current willr is -93.63057325.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
NovaBay Pharmaceuticals Inc Daily Williams %R ChartNovaBay Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of NovaBay Pharmaceuticals Inc. The current atr is 0.02932918.

NovaBay Pharmaceuticals Inc Daily Average True Range (ATR) ChartNovaBay Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of NovaBay Pharmaceuticals Inc. The current obv is 167,143,615.

NovaBay Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartNovaBay Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of NovaBay Pharmaceuticals Inc. The current mfi is 70.24.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
NovaBay Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartNovaBay Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for NovaBay Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-01-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-23STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-31MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

NovaBay Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of NovaBay Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.715
Ma 20Greater thanMa 500.574
Ma 50Greater thanMa 1000.574
Ma 100Greater thanMa 2000.615
OpenGreater thanClose0.550
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Novabay with someone you think should read this too:
  • Are you bullish or bearish on Novabay? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Novabay? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about NovaBay Pharmaceuticals Inc

I send you an email if I find something interesting about NovaBay Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about NovaBay Pharmaceuticals Inc.

Receive notifications about NovaBay Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.